Skip to main content
Login | Suomeksi | På svenska | In English

Browsing by Author "Elsilä, Lauri"

Sort by: Order: Results:

  • Korhonen, Nuppu; Elsilä, Lauri; Hyytiä, Petri; Korpi, Esa (2022)
    While interest in psychedelic drugs in the fields of psychiatry and neuroscience has reemerged in recent last decades, the general understanding of the effects of these drugs remains deficient. In particular, there are gaps in knowledge on executive functions and goal-directed behaviors both in humans and in commonly used animal models. The effects of acute doses of psychedelic lysergic acid diethylamide (LSD) on reward-driven decision making were explored using the mouse version of the Iowa Gambling Task. A total of 15 mice were trained to perform in a touch-screen adaptation of the rodent version of the Iowa Gambling Task, after which single acute doses of LSD (0.025, 0.1, 0.2, 0.4 mg/kg), serotonin 2A receptor-selective agonist 25CN-NBOH (1.5 mg/kg), D-amphetamine (2.0 mg/kg), and saline were administered before the trial. 25CN-NBOH and the three lowest doses of LSD showed no statistically significant changes in option selection or in general functioning during the gambling task trials. The highest dose of LSD (0.4 mg/kg) significantly decreased premature responding and increased the omission rate, but had no effect on option selection in comparison with the saline control. Amphetamine significantly decreased the correct responses and premature responding while increasing the omission rate. In conclusion, mice can perform previously learned, reward-driven decision-making tasks while under the acute influence of LSD at a commonly used dose range.
  • Hynninen, Elina; Moliner, Rafael; Ekelund, Jesper; Korpi, Esa R.; Elsilä, Lauri (2020)
    Psykedeelit eli serotonergiset hallusinogeenit ovat herättäneet uutta mielenkiintoa neurotieteissä ja psykiatriassa viime vuosina. Psykedeelejä tutkitaan nykyään pääsiassa psykedeeliavusteisen terapian muodossa. Tähänastiset tutkimukset antavat viitteitä mahdollisista hoidollisista ominaisuuksista muun muassa masennuksen, ahdistuksen, riippuvuuksien sekä kivun hoidossa. Nykyisten tutkimustulosten mukaan hoidolliset vaikutukset saattavat osalla potilaista jatkua pitkään hoitojakson jälkeen. Psykedeelit sitoutuvat keskushermostossa useisiin välittäjäainereseptoreihin, mutta niiden pääasiallinen molekulaarinen vaikutusmekanismi on serotonergisen 5-HT2A-reseptorin aktivaatio. Subjektiivisesti koetut vaikutukset välittyvät useita eri välittäjäaineita käyttävien hermoratojen toiminnallisten muutosten kautta, toistaiseksi melko huonosti tunnetuilla molekulaarisilla mekanismeilla. Aivotasolla psykedeelien on havaittu vähentävän tärkeiden yhteyskeskusten aktiivisuutta, lisäävän toiminnallisia yhteyksiä korkean tason aistikeskusten välillä sekä lisäävän hermosolujen muovautuvuutta. Psykedeelien voimakkaita psykologisia vaikutuksia ovat muutokset omassa kehonkuvassa ja ympäröivän maailman havainnoinnissa. Lisääntynyt hyvänolontunne, joka kuitenkin voi hetkessä muuttua voimakkaaksi ahdistukseksi on tyypillistä. Psykedeelien aikaansaama kokemus riippuu vahvasti käyttäjän omasta mielentilasta ja käytönaikaisesta ympäristöstä. Yliannostustilanteessa yleisiä haittoja ovat oksentelu, kuume, veren hyytymisen häiriöt, sympaattinen yliaktiivisuus ja lyhyet koomajaksot. Psykedeelejä pidetään fysiologisesti turvallisina aineina, mutta valvomattomissa olosuhteissa psykedeelien käyttäjä voi ajautua voimakkaiden psyykkisten vaikutusten alaisena vaarallisiin tilanteisiin ja onnettomuuksiin. Toleranssi psykedeeleihin kehittyy jo muutaman keskisuuren päivittäisen annoksen jälkeen. Lääketieteellinen psykedeelitutkimus on hyvin alkuvaiheessa. Tutkimukset ovat toistaiseksi olleet otannoiltaan pieniä ja asetelmiltaan usein avoimia ja kontrolloimattomia, minkä vuoksi ne ovat toistaiseksi riittämättömiä kuvastamaaan psykedeelien todellista vaikuttavuutta ja turvallisuutta.
  • Elsilä, Lauri (2018)
    The bed nucleus of the stria terminalis (BNST) is currently widely studied due to its impact in the anxiety-, stress-, and fearrelated behaviours, as well as in addiction. The BNST is highly heterogeneous brain area constituting of set of subnuclei and a variety of neuron populations, properties of which have only partially been revealed by the earlier research. One of the neuron populations, on which only a very little research has been conducted, is the somatostatin (Sst) expressing neurons, highly abundant in the anterodorsal part of the BNST (adBNST), especially in oval and juxtacapsular nuclei of the BNST. This work aims to elucidate the connectivity of this Sst-neuron population, and their role in the behaviours related to BNST activation, particularly the anxiety-, reward-, and drug withdrawal-related behaviours. To specifically study the somatostatin neuron population in the adBNST, I targeted the neurons using stereotaxic delivery of AAV-vectors encoding a myristylated green fluorescent protein (GFP) for neuronal tracing to Sst-Cre-tdTomato reporter line mice (n=2), and Cre-inducible hM3Dq-DREADDs to Sst-IRES-Cre mice (n=21), with Cre-inducible mCherry fluorescent protein as a control (n=20). The mice were treated with activation-inducing 1.0 mg/kg i.p. clozapine-N-oxide (CNO) 30 min prior to the behavioural tests. To assess acute anxiety-like behaviour, I used the elevated-plus maze paradigm and a modified open field test, in which a novel object is introduced to the arena in the middle of the trial. To study the potential effect on reward-associated behaviours, I used the biased conditioned place preference (CPP) test, and for the withdrawal-linked behaviours, we used a method to precipitate the withdrawal symptoms with naltrexone in subchronically morphine-treated mice (n=9 hM3Dq, n=8 control). The neuronal tracing revealed that the adBNST Sst-neurons project to areas known to partake in stress and fear reactions as well as in autonomic and homeostatic control. Namely, projections were seen in medial and central amygdaloidal nuclei, lateral hypothalamus, periaqueductal grey, ventral pallidum, and parabrachial nucleus. In the elevated-plus maze, the CNO-induced activation of the Sst-neurons did not have any effect on the locomotor activity of the mice between the groups. At the same time, Sst activation did not seem to have any significant effect on the time the mice spent in the open arms, nor in the exploratory activities, like the frequency of the head dips or the stretch-attend postures. In line with these results, no effect on the movement between the groups was observed in the open field test. Similarly, no differences in anxiety-related behaviours, like in the time spent in the centre of the arena or in the number of contacts with the novel object during the last phase of the test, were observed. The CPP test failed to show any meaningful rewarding or aversive properties of CNO-induced activation of the Sst-neurons, while the movement rates of the groups during the conditioning trials were not different in statistically significant way. As for the withdrawal symptoms, all the mice showed the predetermined symptoms, but the test failed to show any differences between the study groups. The neuronal tracing revealed connectivity for the adBNST Sst-neurons with brain regions involved in fear- and anxiety behaviour, social encounters, and autonomic control. In spite of this, the CNO-induced chemogenetic activation of the adBNST Sst-neurons failed to show any significant behavioural effects in the chosen paradigms for anxiety-, and reward-related behaviours, and for withdrawal symptoms. Further research is needed to dissect the Sst-subcircuitry of adBNST, both in order to verify the observed output regions, and to elucidate the role these neurons play in modification of behavioural phenotypes.